AgeX Q3 net loss $5.4M; $36M debt converted to preferred; going concern raised

Serina Therapeutics, Inc.

2023-Q3 EPS reported -$0.30 revenue$86,000

Net loss of $5.4M ($0.14 diluted EPS) vs $2.4M loss ($0.06) in Q3 2022.
Cash and equivalents only $0.4M at Sept 30; received $4.4M credit line increase from Juvenescence.
Converted $36M of debt into Series A/B preferred stock in July, eliminating that liability.
Signed merger agreement to acquire Serina Therapeutics; G&A surged due to deal costs.
Company discloses substantial doubt about ability to continue as going concern.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Serina Therapeutics, Inc. reported quarter and nine months ended September 30, 2023 results: net income $5.4 million, or ($0.14) per share (basic and diluted), EPS ($0.14) per share (basic and diluted).

Period: quarter and nine months ended September 30, 2023
Net income: $5.4 million, or ($0.14) per share (basic and diluted)
EPS: ($0.14) per share (basic and diluted)
Result: reported results

Exact text from the filing

AgeX issued a press release announcing its financial results for the quarter and nine months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.